STAAR Surgical Announces Strategic Cooperation Agreement with Senshinkai Eye Institute, A Leading Eye Care Chain in Japan
February 05 2020 - 7:00AM
Business Wire
STAAR Surgical Company (NASDAQ: STAA), a leading developer,
manufacturer and marketer of implantable lenses and companion
delivery systems for the eye, today announced that it entered a
strategic cooperation agreement with Senshinkai Eye Institute
(SEI), an eye care group with five locations in Japan. Like other
strategic cooperation agreements, the agreement includes volume
commitments for the Company’s implantable Collamer lenses (ICLs),
ICL surgeon training and certification, tools for patient education
and co-marketing.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200205005245/en/
Dr. Yoshitaka Oka, Director of the
Senshinkai Eye Institute. (Photo: Business Wire)
“In Japan and globally the significant increase in the myopic
population1 is a megatrend that compromises human quality of life
(QOL) while contributing to socio-economic losses. In my opinion,
we as ophthalmological pioneers must actively work on a safe and
long-term treatment of myopia,” said Yoshitaka Oka, M.D., and
Chairman of Senshinkai Eye Institute, Inc. “STAAR Surgical's EVO
ICL can provide patients with improved visual quality using a
unique and proprietary material with proven long-term stability and
safety. I have been performing ICL surgery since 2010 and have
always believed that ophthalmic care must consider QOL and an
optimal and customized treatment for patients. The EVO ICL family
of lenses is an indispensable partner in achieving these goals and
my treatment of myopia.”
Senshinkai Eye Institute personnel totals 115, including 12
full-time and 20 part-time medical doctors and 17 specialist
optometrists across five locations in the Tokyo, Osaka, and Fukuoka
prefectures.
“We are excited to partner and support Dr. Oka and the
Senshinkai Eye Institute through this new strategic cooperation
agreement,” said Caren Mason, President and CEO of STAAR Surgical.
“Japan is a very important market for STAAR, where, similar to the
United States, the number of laser vision correction procedures has
declined significantly while the need for vision correction remains
high. SEI operates the second largest number of refractive surgery
clinics in Japan. Our goal with SEI and our EVO ICL family of
lenses is to offer as many suitable patients as possible the
opportunity for a lifestyle of visual freedom without the hassles
and costs associated with eyeglasses and disposable contact
lenses.”
Myopia (nearsightedness) is the need for distance vision
correction. STAAR’s lens used in refractive surgery is called an
Implantable Collamer® Lens or “ICL,” which includes the EVO Visian
ICL™ product line. Unlike other procedures, the EVO procedure does
not remove corneal tissue but works in harmony with the natural
eye. EVO rests behind the iris and is biocompatible. 99.4% of
patients in a Patient Registry said they would have the ICL
procedure again.2
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 30 years, designs, develops, manufactures and markets
implantable lenses for the eye with companion delivery systems.
These lenses are intended to provide visual freedom for patients,
lessening or eliminating the reliance on eyeglasses or contact
lenses. All of these lenses are foldable, which permits the surgeon
to insert them through a small incision. STAAR’s lens used in
refractive surgery is called an Implantable Collamer® Lens or
“ICL,” which includes the EVO Visian ICL™ product line. More than
1,000,000 Visian® ICLs have been implanted to date and STAAR
markets these lenses in over 75 countries. To learn more about the
ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA,
the company operates manufacturing and packaging facilities in
Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more
information, please visit the Company’s website at
www.staar.com.
About Senshinkai Eye
Institute
Senshinkai Eye Institute, Inc. (SEI) operates five eye clinics
in the Tokyo, Osaka, and Fukuoka prefectures, treating a wide range
of ophthalmologic symptoms. SEI specializes in Femto-Second Laser
Assisted Cataract Surgery (FLACS), Minimally Invasive Glaucoma
Surgery (MIGS), Vitreous Surgery (VIT), and Refractive Surgery such
as EVO ICL, LASIK and PRK. SEI and its clinics focus on advancing
surgical technologies and equipment for enhancing patients'
experience and outstanding satisfaction through continuous
operational excellence, contributing to clinical practice and
theories in ophthalmology. For more information, please visit the
Senshinkai Eye Institute websites at senshinkai-clinic.jp or
okaganka.com.
ATTENTION:
For Physicians: Please reference the Visian ICL Product
Information for a complete listing of indications, warnings, and
precautions.
For Patients: Before considering Visian ICL surgery you should
talk with your eye care professional about Visian ICL surgery,
especially the potential benefits, risks, and complications.
1 Holden at al. (2016), “Global Prevalence of Myopia and High
Myopia and Temporal Trends from 2000 through 2050”, Ophthalmology,
Volume 124, Issue 5, pp 1036-1042 2 Patient Registry data on
file.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200205005245/en/
Investors & Media Brian Moore Sr. Director, Investor,
Media Relations and Corporate Development (626) 303-7902, Ext. 3023
bmoore@staar.com
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Aug 2024 to Sep 2024
STAAR Surgical (NASDAQ:STAA)
Historical Stock Chart
From Sep 2023 to Sep 2024